Increasing Optionality For Licensors, Rise Of Small-Cap Partners Ongoing
Executive Summary
Companies with market caps below $1bn continue to represent a growing percentage of biopharma deal-making, giving firms looking to license or partner assets increased optionality, Inventiv Health's Neel Patel told a session at BIO 2017.
You may also be interested in...
BIO Notebook, Day 2: Deal Insights, A Payer Perspective And EMA Rumors
In the spirit of the BIO International Convention's partnering focus, Scrip covered a dealmaker survey and spoke to Bayer about some of its business development priorities on day two of the annual convention. We also report on a payer perspective, post-Brexit EMA rumors and investments in vaccines.
Sun sets on Schering-Plough as Merck closes $41 billion merger
Merck & Co has completed its $41 billion merger with Schering-Plough.
Deal Watch: Six Small Biopharma Mergers Reflect Recent Trend
M&A edition: Mergers by Century/Clade, Eliem/Tenet, Kintara/TuHURA, Aditxt/Appili, Onconova/Traws and Apotex/Searchlight follow other companies joining forces in a tight cash environment.